Sarcoma research 

  • About our sarcoma research

    Research is an important part of a large sarcoma service, and so we run many clinical trials. These investigate new drugs that may be useful in sarcoma, or new ways of giving established treatments such as surgery, chemotherapy or radiotherapy. We can also have trials trying to find out more about sarcomas, by asking patients if we can use a sample of their tumour and/or a blood test to learn more about how these cancers develop. All our patients are given the opportunity to take part in any clinical trials for which they are suitable if they wish.

    Clinical trials are a very important part of cancer treatment. They allow us to learn about new drugs and treatments, and how they should fit in with current treatments, in a controlled way. They also help us to learn how best to use the treatments that we have. Clinical trials are important for patients as it allows them to try new drugs or treatments that they couldn't otherwise access. At UCLH we run a large number of clinical trials for both bone sarcomas and soft tissue sarcomas. We have a team of clinical trial practitioners, a paediatric cancer research nurse, and a data manager to run the studies and oversee patients while they are taking part in studies.

    Clinical Trials Practitioners

    • Maria Power
    • Sarah Taylor
    • Chloe Walding
    • Swad Timbo

    Data Manager

    • Elizabeth Adenipekun
  • Currently open trials

    AFATINIB FOR CHORDOMA: A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma

    ANITA: A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor Nintedanib with the intravenous cytotoxic compound Ifosfamide for treatment of patients with advanced, metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based firstline chemotherapy for inoperable disease 

    ESPRIT: ESP1/SARC025 Global Collaboration: A phase I study of a combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in patients with previously treated, incurable Ewing sarcoma

    EE 2012: an international randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours

    EZH202: A phase II, multicentre study of the EZH202 inhibitor Tazemetostat in adult subjects with INI1-negative tumours or relapsed refractory synovial and epitheliod type.

    HGUS EORTC 62113: A randomised double-blind phase II study evaluating the role of maintenance Cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) or response to Doxorubicin +/-Ifosfamide or in metastatic first line treatment

    HOPE: Phase I/II study of Lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma

    IMRIS: A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma

    Kindred Study: The international sarcoma kindred study: a global multi-site prospective cancer genetics study
    KCP-330-020 (SEAL): A phase II/III multicentre, randomised, double-blind study of Selinexor (KPT - 330) verus placebo in patient with advanced unresectable differentiated liposarcoma
    RAPPER: Radiogenomics: Assessment of polymorphisms for predicting the effects of radiotherapy

    rEECUr: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

    SSG XXII: A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor Imastinib Mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence

    Sometimes there may be other trials open - it is always worth asking your doctor.

  • Recently closed trials

    ALT-GIST: A randomized phase II trial of Imatinib ALTernating with Regorafenib compared to Imatinib alone for first line treatment of advanced gastrointestinal stromal tumour (GIST)

    ANNOUNCE 2: A phase Ib (open label)/phase II (only) randomized, double-blinded study evaluating the efficacy of Gemcitabine and Docetaxel with or without a human anti-PDGFRa monoclonal antibody (Olaratumab) in the treatment of advanced soft tissue sarcoma (Academic)

    Bone Sarcoma CTC study: Optimisation of circulating tumour cell detection in bone sarcomas

    CaboGIST EORTC 1317: Phase II study of Cabozantinib in patients with metastatic gastrointestinal stromal tumour (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with Imatinib and Suntinib

    CASPS: A phase II trial of Cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS). This trial is testing a new drug Cediranib that has already shown promising results in a small number of patients with alveolar soft part sarcoma. Cedirinib works by inhibiting growth of blood vessels in tumours.

    CREATE: a cross-tumoral phase II trial exploring Crizotinub (PF-02341066) in patients with advanced tumours induced by casual alterations of ALK and/or MET

    GOG-0277: A phase III randomised trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus observation for uterus-limited, high grade uterine leiomyosarcoma

    Paragon: a phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms

    RMS 2005: A protocol for non-metastatic rhabdomyosarcoma. This study is investigating the use of chemotherapy in the treatment of children and teenagers with rhabdomyosaroma that has not spread around the body

    VIT 0910: International randomized phase II trial of the combination of Vincristine and Ironotecan with or without Temozolomide (VI or VIT) in children and adults with refractory or relapsed rhabdosarcoma